Chester “Chip” Davis, Jr. is the President and Chief Executive Officer of the Association for Accessible Medicines (AAM), the nation’s leading trade association for manufacturers and distributors of generic prescription drugs, manufacturers of bulk active pharmaceutical chemicals and suppliers of other goods and services to the generic drug industry. Appointed to the position by the AAM Board in summer 2015, Chip is responsible for ensuring that the association fulfils its primary mission, which is to improve the lives of patients and consumers by providing timely access to safe, effective and affordable medicines.
Prior to joining AAM, Chip most recently served as Executive Vice President for Advocacy and Member Relations at the Pharmaceutical Research and Manufacturers of America (PhRMA), where he was responsible for leading PhRMA’s federal, state and international government relations and advocacy efforts, in addition to member company recruitment and retention. Prior to joining PhRMA, he was Vice President of Corporate External Relations for AstraZeneca, where he oversaw the company’s government relations, strategic alliances, community relations and employee volunteer efforts. He was a member of AstraZeneca’s Corporate Affairs Leadership team and Vice Chairman of the company’s Political Action Committee. In 2007, Chip was one of the inaugural winners of the AstraZeneca CEO Award, given to global executives who best demonstrate AstraZeneca leadership capabilities in their accomplishments.
Chip earned an undergraduate degree in Accounting from the University of Delaware, and a Juris Doctor from the University of Baltimore School of Law. He is a licensed attorney in Maryland, Virginia and the District of Columbia. He currently serves on the board of directors for the Washington, D.C. area Chapter of Autism Speaks, the University of Delaware Alumni Association and the St. Mary’s High School Royal Blue Club, and the member advisory board for the National Journal.